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Isotope imaging of the metabolism of different anatomic
structures has been applied as a diagnostic tool in
oncology for a number of years. During the 1970’ and
the 1980’s positron emission tomography (PET) was
considered inferior to computed tomography (CT) and
magnetic resonance imaging (MRI) due to its poor
resolution and technical difficulties arising from short
isotope half-life. The beginning of the 1990’s saw the
introduction of 18-F-fluorodeoxyglucose – a fluorine
isotope-labeled glucose metabolite – which provided
a breakthrough point for PET.
The value of FDG-PET in the diagnosis and staging
of non-small cell lung cancer (NSCLC) has been the
subject of numerous clinical trails since the mid-nineties.
Its sensitivity and specificity for differentiating pulmonary
lesions recognised in CT is 93-100% and 63-90%,
respectively [1-3]. Such high sensitivity assures a very low
probability of the presence of a malignant lesion within
areas that are free of pathologic isotopic marker uptake.
The reason for false positive results is usually the presence
of specific or non-specific inflammatory infiltrations of
the lungs. FDG-PET has also improved the diagnostics of
NSCLC metastases to the mediastinal lymph nodes. Acc.
to Vansteenkiste the sensitivity of PET and CT was 89%
and 79 % respectively, while their specificity – 99% and
54%, respectively [4]. Pieterman reported similar results
[5] – with the sensitivity of PET and CT reaching 91% and
75%, respectively and specificity – 86% and 66%,
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A i m.  Positron emission tomography imaging significantly improves the accuracy of clinical staging in patients with non-small-
cell lung cancer (NSCLC). The aim of the study was to evaluate the alterations in target volume (GTV) contouring based on
computed tomography images and PET/CT fusion during radiotherapy planning in NSCLC patients.
M a t e r i a l  a n d  m e t h o d s.  We performed a retrospective study of 20 diagnostic FDG-PET/CT examinations performed in
NSCLC patients between September 2003 and July 2005. FDG-PET studies were performed on an integrated Biograph SL
(Siemens) PET/CT scanner to assess clinical staging additionally to conventional images. The first stage included spiral
computed tomography, FDG-PET examination was performed as stage two, without repositioning the patient. In the course
of the retrospective study the PET and CT data were sent to the Eclipse 7.1 radiotherapy planning system and registered using
the same coordinate system (DICOM ORIGIN). First, the target volume (GTV) was contoured on the platform of the CT
images. The GTV/CT volume included the primary tumor and mediastinal lymph nodes exceeding 10 mm in the maximal
diameter.Then the GTV volume was contoured using PET/CT fusion images. The GTV/PET volume included foci of
pathological FDG uptake and the, primary tumor mass with the involved mediastinal lymph nodes as seen on the CT with
enlarged lymph nodes discerned independently of FDG uptake.
R e s u l t s.  The incorporation of PET/CT fusion images into target contouring volumes led to volume change in all study
patients with GTV/PET volume reduction in 16 cases (group I) (caused by differentiating neoplastic lesions from atelectasis,
fibrosis, pleural effusions and mediastinal organ displacement). Mean difference between GTV/CT and GTV/PET in this group
was 53 cm3 (range: 0.3 cm3 to 148 cm3), i.e. 45% (3%-82%) of the primary GTV/CT volume. In this group, in 14 cases the
changes exceeded 17% of the GTV/CT volume. In the remaining 4 cases the FDG/PET images caused an increase in the
GTV/PET volume due to the incorporation of new groups of involved mediastinal lymph nodes. The mean difference
between GTV/CT and GTV/PET was 18 cm3 (range: 9 cm3 to 35 cm3), i.e. 32% (10%-80%) of the primary GTV/CT
volume.
C o n c l u s i o n s.  Positron emission tomography cannot replace morphological imaging, yet it provides additional data
concerning the pathological lesions. PET/CT fusion images used for radiotherapy planning in NSCLC patients significantly
affect thee GTV target volume.
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respectively. The results obtained in the course of PET
and CT were, in the course of both these studies,
confirmed pathologically while the differences achieved
statistical significance. The additional value of PET lies in
the possibility of performing whole body imaging, which in
some 19 to 29% of patients allows discerning unsuspected
metastatic lesions. [6,7]. Thus PET results may alter TNM
grading based on conventional diagnostic methods in as
many as 30-40% of cases [6, 7] and acc. to the results of
the “Onco-PET III” trial – change the therapeutic
strategy in 18% of patients.
Radiotherapy planning involving PET and CT image
fusion has been applied in the course of treatment of
head and neck cancers, rectal cancer and female genital
cancers, however a majority of papers concerning this
issue deal with NSCLC, due to the unquestionable value
of FDG-PET in this particular malignancy.
Aim
The aim of the study was to present the differences in
target volume (GTV) contouring based upon CT imaging
and upon PET/CT image fusion in the course of
radiotherapy planning in patients with NSCLC
Material and methods
We performed a retrospective analysis of PET/CT scan results
obtained from 20 NSCLC patients (18 men, 2 women, mean
age: 60 yrs.) between September 2003 and July 2005 at the Dept.
of Nuclear Medicine of the Centre of Oncology in Bydgoszcz,
Poland. The scans were performed to assess the clinical stage of
the disease and were intended to complement conventional
diagnostics – chest CT, bronchoscopy, abdominal ultrasound
and laboratory tests. In all cases the results of the chest CT did
not allow to assess local advancement. In all cases the diagnosis
of cancer had been confirmed by pathological examination of
bronchial tissue samples obtained in the course of bronchoscopy
– 14/20 cases of carcinoma planoepitheliale, 4/20 – of adeno-
carcinoma and 2/20 – of NSCLC with no type. TNM staging
was based on the results of conventional diagnostic methods
(Table I).
10/20 patients underwent radical surgical treatment, (of
whom 3 received preoperative chemotherapy). Radical radio-
therapy was performed in 5/20cases (with 3 patients receiving
radio-chemotherapy). The remaining 5/20 patients received
palliative treatment only. In the case of 6 patients we performed
PET/CT in order to assess the degree of remission after
neoadjuvant chemotherapy, while in the case of another 2
patients – to investigate the possibility of failure 12 and 46
months, respectively, after surgical treatment.
The scans were performed using an integrated Biograph SL
PET/CT scanner (Siemens). Before the scan the patients
were administered 18-F-fluorodeoxyglucose i.v. (4.5-5 MBq/kg
b.w.). In the first stage we performed spiral CT without contrast
from the crown of the skull to the mid-femur. In the second
stage PET scanning was performed over the same area without
patient repositioning, using 4-5 different bed positions. After
obtaining a fusion of the functional PET scans and
morphological CT scans the results were analysed by nuclear
medicine specialists.
For the purpose of further retrospective studies the PET
and CT data was fed into the Eclipse 7.1 planning system using
DICOM RT protocols and registered using the same coordinate
system (DICOM ORIGIN). The first stage of the analysis
consisted of contouring the target volume (GTV) on the
platform of the CT images. The GTV/CT included the primary
tumour and mediastinal lymph nodes exceeding 10 mm in
diameter. In the course of the second stage of the analysis the
GTV/PET volume was contoured using PET/CT image fusion.
The GTV/PET volume included foci of pathological glucose
uptake and corresponded to the CT image of the primary
tumour mass, metastatic lymph nodes and all mediastinal lymph
nodes fulfilling the criteria of metastatic involvement (i.e.
exceeding 10 mm in the maximal axis) independently of the
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Table I. Patient characteristics
Pts/Nr Age/sex H-P TNM Treatment before PET/CT
1 78/M non-small T4N2M0 none
2 69/M non-small T3N0M0 CHTHx6
3 55/F adeno-ca T2N2M1 lobectomy, RT50Gy, CHTHx6,relapse
4 51/M squamous T2N2M0 none
5 75/M adeno-ca T2N0M0 none
6 57/M squamous T4N2M0 none
7 63/M squamous T4N3M0 none
8 58/F squamous T2N0M0 lobectomy, relapse
9 57/M squamous T2N2M0 none
10 55/M squamous T2N2M0 none
11 46/M adeno-ca T2N2M0 CHTHx3
12 53/M adeno-ca T1N0M0 none
13 62/M squamous T4N1M0 none
14 64/M squamous T2N2M0 none
15 55/M squamous T1N2M0 CHTHx3
16 58/M squamous T3N2M0 CHTHx3
17 64/M squamous T3N2M0 none
18 58/M squamous T2N2M0 CHTHx4
19 66/M squamous T3N2M0 CHTHx3
20 50/M squamous T3N2M0 CHTHx6
FDG uptake. In both cases we additionally relied on clinical
data and on the results of additional tests.
The Eclipse planning system was used to perform
calculations of the GTV/CT and GTV/PET volumes and to
calculate the differences between them. We also assessed their
common volume i.e. the volume representing the overlapping of
the GTV/CT and the modified volume calculated in the course
of PET/CT image fusion.
Results
The inclusion of PET/CT image fusion results into GTV
contouring resulted in GTV alteration in all the studied
patients (Table II). GTV/PET was decresed in 16 patients
(Group 1). This was caused by the possibility to diffe-
rentiate between metabolically active tumour invasion
and areas of fibrosis, atelectasis, effusion or displacement
of mediastinal structures. The mean calculated difference
in volume between GTV/CT and GTV/PET values was 53
cm3 (range: 0.3-148 cm3), i.e. 45% (3-28%) of the original
GTV/CT volume. In 14/16 Group I patients the volume of
the lesions exceeded 17% of the GTV/CT.
In the case of the remaining 4 patients the use of
FDG/PET caused a GTV increase. GTV/PET was in
these cases greater due to the diagnosis of additional
groups of involved mediastinal nodes which could not be
found in CT. The mean calculated difference in volume
between GTV/CT and GTV/PET values was 18 cm3
(range: 9-35 cm3), i.e. 32% (10-80%) greater than the
original GTV/CT volume. (Figure 1).
In 6/20 cases the differences between GTV/CT and
GTV/PET were the result of a calculation combining
both a decrease in volume associated with differentiating
adjacent benign masses and an increase caused by the
discovery of involved mediastinal nodes. In 9 cases of
CT-occult mediastinal nodal metastases the FDG/PET
discerned pathological glucose uptake which would have
remained outside the GTV/CT. Eclipse contouring
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Table II Comparison of the target volumes contoured on the platform of computed tomography (GTV/CT) 
and positron emission tomography computed tomography (GTV/PET)
Pts GTV/CT GTV/ PET GTV difference Common target volumes Cause of GTV change
Nr cm3 cm3 cm3 / % cm3 / %
1 177 196 19 / 11Î 160 / 90 Mediastinal lymph nodes
2 88 30 58 / 66↓ 28 / 93 Atelectasis, pleural effiusion
3 59 34 25 / 42↓ 32 / 94 Relapse,fibrosis,mediastinal displacement
4 32 41 9 / 28Î 29 / 91 Mediastinal lymph nodes
5 115 35 80 / 70↓ 32 / 91 Atelectasis
6 351 250 101 / 29↓ 215 / 86 Mediastinal invasion
7 396 295 101 / 40↓ 241 / 88 Atelectasis, mediastinal lymph nodes
8 42 19 23 / 55↓ 16 / 84 Relapse, mediastinal displacement, fibrosis
9 105 115 10 / 10Î 97 / 92 Mediastinal lymph nodes
10 105 19 86 / 82↓ 19 / 100 Atelectasis
11 30 25 5 / 17↓ 20 / 80 Atelectasis, mediastinal lymph nodes
12 10.4 10.1 0.3 / 3↓ 7 / 69 No changes
13 254 106 148 / 58↓ 105 / 99 Atelectasis
14 97 24 73 / 75↓ 19 / 79 Mediastinal invasion
15 8 7 1 / 13↓ 4 / 57 No changes
16 89 37 52 / 58↓ 37 / 100 Atelectasis, mediastinal invasion, mediastinal lymph nodes
17 116 65 51 / 44↓ 63 / 97 Mediastinal invasion
18 61 34 27 / 44↓ 33 / 97 Fibrosis, mediastinal lymph nodes
19 69 51 18 / 26↓ 35 / 69 Atelectasis, mediastinal lymph nodes
20 9 44 35 / 80Î 9 / 100 Fibrosis, mediastinal lymph nodes
Î – increase of GTV/PET volume to GTV/CT
↓ – decrease of GTV/PET volumesto GTV/CT
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Figure 1. Comparison of target volumes GTV/CT and GTV/PET for
indyvidual patients
allowed to contour a common volume for GTV/CT and
GTV/PET. In patients from group 1 (i.e. with decreased
GTV) the mean common volume was 57 cm3 (range: 4-
241 cm3), i.e. 88% of the GTV/PET value. In group 2
(i.e. with increases GTV) the mean common volume was
74 cm3 (range: 9-160 cm3). (Figure 2).
Discussion
Precise staging of the disease is one of the basic
conditions of correct treatment planning in the course
of radical radiotherapy for NSCLC. The reasons for the
inclusion of PET/CT image fusion into treatment
planning include the identification of patients who are
ineligible because of disseminated disease and the precise
imaging of the range of malignant lesions within the
thorax, thus reducing normal tissue irradiation, limiting
the risk of committing a geographic mistake and
escalating the total delivered dose. PET/CT is especially
valuable in advanced cases of NSCLC, as a means for
radical radiotherapy qualification. In case of conventional
staging the frequency of finding unsuspected distant
metastases in PET scans is significantly higher in stage II
patients than in stage I and II patients and reaches 24%
[7].
We have presented a comparison of GTVs contoured
conventionally according to the results of CT scans with
GTVs contoured according to PET and CT image fusion.
Scanning was performed with an integrated PET/CT
scanner which performs CT and PET in the course of
the same session, in a short time, without patient
repositioning. Such apparatus minimalises errors which
may occur during image fusion and increases the
diagnostic accuracy through the localisation of areas of
pathologic glucose uptake within the anatomical
structures [9].
Radiotherapy planning with the aid of a CT/PET
scanner does not differ from typical CT-based treatment
planning. The modification of the shapes and sizes of
GTVs was brought on by the recognition of additional
nodal groups which could not be found in CT scans and
by the possibility of differentiating benign lesions in the
direct vicinity of malignant masses.
The number of literature reports concerning
PET/CT image fusion in radiotherapy treatment planning
increases as PET becomes more available. Studies
presenting the comparisons of the volumes and shapes
of GTV and PTVs contoured according to CT and
PET/CT image fusion were performed on various types of
apparatus with various resolution (PET scanners or
gamma-cameras). Although the study designs differed as
to the methods of CT and PET image fusion, patient
positioning and result analysis, yet in all cases the authors
have reported that PET/CT image fusion causes
significant modifications of the GTVs in as many as 40%
to 100% of patients [10-17].
In the course of an analysis of 73 patients with N2
tumours confirmed in CT and/or PET Vanuytsel observed
significant GTV changes associated with PET/CT image
fusion in 45 cases (62%), with an increase in 16 cases
(22%) and a decrease in 29 cases (40%). The mean value
of PTV volume reduction assessed in the first 10 patients
from this group was 29±18%, range: 12-66% [10].
Bradley reported similar results of a prospective
study, where a significant change in GTV was observed in
14/24 patients (58%) [11]. In the remaining 10 patients
the differences ranged from 1 cm3 to 56 cm3 and referred
to as minimal, yet GTV corrections enforced by PET/CT
image fusion were performed in all the patients. Giroud
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Figure 2. Common target volumes for GTV/CT and GTV/PET for
indyvidual patients
Figure3a
Figures 3A and 3B. Neoplastic lesion with pathological FDG uptake in the FDG-PET study is included in the GTV target volume defined on the
platform of CT
Figure 3b
reported significant GTV changes in 5/12 patients (41%)
[12]. A decrease in GTV observed I 3 cases and presented
as V95 was 59% on average.
In her prospective study Mah has documented that
the application of PET for treatment planning has
significantly altered treatment strategy in 12/30 patients
(40%) [13]. 7 patients were referred for palliative
treatment, instead of the originally prescribed radical
treatment, due to up-staging after FDG-PET imaging.
The PTV size defined using PET/CT image fusion did
not match the PTV/CT-associated size in 17-29% of the
patients, these variations arising from the different
interpretations supplied by three independent oncologists
employed I the course of the trial.
Treatment planning using the integrated PET/CT
scanner does not require patient repositioning during the
PET and CT scans and allows minimalising the errors
occurring during image fusion [14]. IN the course of our
study these conditions were similar. Ciernik conducted
a study using an integrated PET/CT scanner on 31
patients, 6 of whom had NSCLC. Mean GTV/CT and
GTV/PET values were 36.1 and 27.8%, respectively.
PET/CT image fusion allowed to reduce the GTV in 4
patients as it had allowed differentiating between
neoplastic infiltration and atelectasis. In the case of one
patient mediastinal metastatic nodes were found with
PET, thus allowing avoiding a geographic error.
The number of patients with altered (increased or
decreased) GTVs after PET/CT image fusion contouring
differs in the reports of different authors due to the fact
that the patient groups were heterogeneous as to the
stage of clinical advancement. In our patient material
diagnostic PET was performed in patients in case of
whom we suffered doubt as to the extent of disease
invasion within the thorax. In all cases the malignant
masses neighboured benign lesions – atelectasis, fibrosis,
effusion or mediastinal dislocation rendering image
interpretation difficult. What is more, the method of data
analysis applied in a number of cases omitted minor
corrections of the GTV values which have been included
I this analysis. This explains our high ratio of patients
with GTV/PET correction (100%), as compared to that
reported by other authors (40-100%). Among the 16
patients with GTV/PET decrease in as many as 14 cases
the reduction exceeded 17% of the original GTV/CT.
Among the other 4 patients the alterations were caused by
the recognition of additional nodal groups and their
inclusion into the theoretic high-dose field. In 5 cases the
final target volume and shape (GTV/PET) was
extrapolated from a decrease caused by the differentiation
of benign lesions and an increase brought on by the
recognition of involved mediastinal nods. All in all
without the PET/CT image fusion involved nodal masses
would have remained outside the target area in as many
as 9 cases.
The parameter of GTV/CT and GTV/PET common
volume, which describes the degree of shape modification
of the final target volume, has not been discussed in any
previous studies. In our material in group 1 (16 pts) the
common volume was 88% of the modified GVT/PET,
while in group 2 (4 pts.) it accounted for 91%.
Conclusions
Positron emission tomography cannot take the place of
morphologic imaging but it provides additional data
concerning the character of observed pathologies. The
application of PET/CT image fusion for radiotherapy
treatment planning in patients with NSCLC has
a significant impact on the GTVs.
Aleksandra Lewandowska MD, PhD
Department of Teleradiotherapy
Cancer Center in Bydgoszcz,
Romanowskiej 2, 85-796 Bydgoszcz, Poland
e-mail: alekslewandowska@wp.pl
References
1. Knight SB, Delbeke D, Stewart JR et al. Evaluation of pulmonary lesions
with FDG-PET. Comparison of findings in patients with and without
a history of prior malignancy. Chest 1996; 109: 982-8.
2. Lowe VJ, Fletcher JW, Gobar L et al. Prospective investigation of positron
emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-84.
3. Imdahl A, Jenkner S, Brink I et al. Validation of FDG positron emission
tomography for differentiation of unknown pulmonary lesions. Eur J
Cardio Thor Surg 2001; 20: 324-9.
4. Vansteenkiste JF, Mortelmans LA. FDG-PET in the locoregional lymph
node staging of non-small cell lung cancer: a comprehensive review of the
Leuven lung cancer group experience. Clin Pos Imag 1999; 2: 223-31.
5. Pieterman RM, Van Putten JW, Meuzelaar JJ et al. Preoperative staging
of non-small-cell lung cancer with positron-emission tomography. N Engl
J Med 2000; 343: 254-61.
6. Lewis P, Griffin S, Marsden P et al. Whole-body 18F-fluorodeoxyglucose
positron emission tomography in preoperative evaluation of lung cacer.
Lancet 1994; 344: 1265-6.
7. Mac Manus MP, Hicks RJ, Matthews JP et al. High rate of detection of
unsuspected distant metastases by PET in apparent stage III non-small-
cell lung cancer: implications for radical radiation therapy. Int J Radiat
Oncol Biol Phys 2001; 50: 287-93.
8. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd
German Interdisciplinary Consensus Conference „Onko-PET III”. 21
July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
263
Figure 4. Fusion of FDG-PET and CT images shows mediastinal
lymph node metastases undiscerned in computed tomography
9. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung
cancer with integrated positron-emission tomography and computed
tomography. N Engl J Med 2003; 348: 2500-7.
10. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al. The impact of 18F-
fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)
lymph node staging on the radiation treatment volumes in patients with
non-small cell lung cancer. Radiother Oncol 2000; 55: 317-24.
11. Bradley J, Thorstad WL, Mutic S et al. Impact of FDG-PET on radiation
therapy volume delineation in non-small-cell lung cancer. Int J Radiat
Oncol Biol Phys 2004; 59: 78-86.
12. Giraud P, Grahek D, Montravers F et al. CT and 18F-deoxyglucose
(FDG) image fusion for optimization of conformal radiotherapy of lung
cancers. Int J Radiat Oncol Biol Phys 2001; 49: 1249-57.
13. Mah K, Caldwell CB, UNG YC et al. The impact of 18FDG-PET on
target and critical organs in CT-based treatment planning of patients
with poorly defined non-small-cell lung carcinoma: a prospective study. Int
J Radiat Oncol Biol Phys 2002; 52: 339-50.
14. Ciernik F, Dizendorf E, Baumert BG et al. Radiation treatment planning
with an integrated positron emission and computed tomography
(PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57: 853-
63.
15. Erdi YE, Rosenzweig K, Erdi AK et al. Radiotherapy treatment planning
for patients with non-small cell lung cancer using positron emission
tomography (PET). Radiother Oncol 2002; 62: 51-60.
16. Caldwell CB, Mah K, Ung YC et al. Observer variation in contouring
gross tumor volume in patients with poorly defined non-small-cell lung
tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat
Oncol Biol Phys 2001; 51: 923-31.
17. Nestle U, Walter K, Schmidt S et al. 18F-Deoxyglucose Positron Emission
Tomography (FDG-PET) for the planning of radiotherapy in lung cancer:
high impact in patients with atelectasis.. Int J Radiat Oncol Biol Phys
1999; 44: 593-7.
Paper received: 11 January 2006
Accepted: 29 March 2006
264
